Market Research Report
Testosterone Replacement Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024
|Published by||Transparency Market Research||Product code||367370|
|Published||Content info||127 Pages
Delivery time: 1-2 business days
|Testosterone Replacement Therapy Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 - 2024|
|Published: July 11, 2016||Content info: 127 Pages||
A wide range of testosterone replacement therapy (TRT) products containing different active ingredients have been made available by a large number of both global and local manufacturers. With various studies estimating the number of men affected by hypogonadism (testosterone deficiency) at 30% worldwide, the demand for TRT is poised to increase gradually in the years ahead. The condition primarily affects men aged between 40 and 79 years, making this demographic a key target segment for market players.
However, the market is currently at a crucial juncture with top performing products losing their patents in the next few years. This will no doubt cause a major dent in revenues of key market players. However, some of this impact could be reduced by the heightened demand for and awareness levels about the benefits of advanced TRT products. Many of these products are now being utilized in testosterone deficiency treatment are likely to support market growth during the forecast period.
For the purpose of this study, the global testosterone replacement therapy market has been segmented on the basis of product type into creams/gels, patches, injections, gums/buccal adhesives, implants and oral drug forms. Of these, the creams/gels segment led the global market, as overall sales were mainly impelled by key branded formulations such as AndroGel from AbbVie, Inc. Axiron from Eli Lilly and Company, and Fortesta, Testim, and Natesto from Endo Pharmaceuticals Inc.
Ease of use and comparatively less side effects have been the winning characteristics of gels/cream TRT products. However, this segment is expected to lose its current hold on the market owing to patent expirations of branded formulations.
TMR expects the injections product segment to witness the fastest CAGR from 2016 to 2024. This will be possible mainly because consumers are now more open to using these low priced products - a factor aided by the increasing availability of self-administered forms of these products globally.
On the basis of active ingredients, the TRT market is segmented into testosterone, methyl testosterone, testosterone undecanoate, and testosterone enanthate and testosterone cypionate. Of these, testosterone as an active ingredient dominated the global TRT market in 2015. However, other active ingredients are expected to cover much ground through the forecast period. The demand for ester forms of testosterone such as testosterone cypionate and testosterone undecanoate is projected to show a healthy rise. Testosterone undecanoate is expected to witness the fastest growth through the report's forecasting horizon from 2016 to 2024.
Of the five broad geographical segments of the global testosterone replacement therapy market, North America accounted for the largest share (84.7%) of the market and was followed by Europe In 2015. The other key segments are Europe, Asia Pacific, Middle East and Africa (MEA), and Latin America.
The demand for advanced TRT products was especially strong in the U.S. in 2015 as the country accounted for 95% of the North America TRT market in that year, TMR has observed. Asia Pacific will greatly benefit from higher healthcare investments being channeled into the region and is expected to witness the fastest CAGR in the TRT market during the forecast period. China and India are markets that companies in the TRT market cannot ignore. In South Korea and Japan, on the other hand, the sizeable geriatric population and strong positive sentiments will aid the consumption of TRT products. Brazil is the key TRT market in Latin America with the single largest share 2015.
The key players operating in the global testosterone replacement therapy market are AbbVie, Inc., Allergan plc, Bayer AG, Endo Pharmaceuticals, Inc., Eli Lilly and Company, Kyowa Kirin International plc, Mylan N.V., Novartis AG, and Pfizer, Inc. The testosterone replacement therapy market is somewhat consolidated with presence of a few large global players and some local vendors that are operating in the international market.
This report on testosterone replacement therapy studies the current as well as future prospects of the market globally. The stakeholders of this report include companies and intermediaries engaged in the manufacture and commercialization of various testosterone replacement therapy products as well as new entrants planning to enter this market. This report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments and sub-segments considered within the scope of the study. This section also provides the overall information and data analysis of the global testosterone replacement therapy (TRT) market with respect to the leading market segments based on major products, key active ingredients and geographies.
The global testosterone replacement therapy market has been studied based on major TRT product segments, active ingredient segments, and their regional as well as national markets. Based on product type, the global market has been categorized into six major segments: creams/gels, patches, injections, gums/buccal adhesives, implants and oral. Based on active ingredient type, the global market has been categorized into five major segments: testosterone, methyl testosterone, testosterone undecanoate, and testosterone enanthate and testosterone cypionate. The market for these segments has been extensively analyzed based on their utility, effectiveness, sales, and geographic presence. Market revenue in terms of US$ Mn for the period from 2014 to 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 are provided for all segments, considering 2015 as the base year.
The market overview section of the report explores the market dynamics such as drivers, restraints, and opportunities that currently have a strong impact on the global testosterone replacement therapy market and could influence the market in the near future. Market attractiveness analysis has been provided in the market overview section in order to explain the intensity of competition in the market across different geographies. The competitive scenario among different market players is evaluated through market share analysis in the competitive landscape section of the report. All these factors would help market players to take strategic decisions in order to strengthen their positions and expand their shares in the global market. Geographically, the testosterone replacement therapy market has been segmented into five regions: North America, Europe, Asia Pacific, Middle East and Africa (MEA) and Latin America. Each regional market for testosterone replacement therapy has been further categorized into major product and active ingredient segments considered within the scope of the study. Key country (U.S., Japan, Germany, U.K., Canada, China, Brazil, Mexico and UAE) market revenues have also been provided in a separate country snippets chapter of the report. Market revenue in terms of US$ Mn for the period from 2014 to 2024 along with CAGR % from 2016 to 2024 are provided for all the regions and nations considering 2015 as the base year.
The report also profiles key players operating in the testosterone replacement therapy market based on various attributes such as company overview, financial overview, business strategies, product portfolio, and recent developments. Major players profiled in this report include AbbVie, Inc., Allergan plc, Bayer AG, Endo Pharmaceuticals, Inc., Eli Lilly and Company, Kyowa Kirin International plc, Mylan N.V., Novartis AG, and Pfizer, Inc.
The global testosterone replacement therapy market is segmented as follows: